REFERENCES
- Lee C W, Buckley F, Costello S, Kelly S. A systematic review of the characteristics of randomized control trials featuring prostaglandins for the treatment of glaucoma. Curr Med Res Opin 2008; 8: 2265–2270
- Rao V P, Epstein D L. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 2007; 21: 167–177
- Koga T, Koga T, Awai M, et al. Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction, and motility in cultured human trabecular meshwork cells. Exp Eye Res 2006; 82: 362–370
- Waki M, Yoshida Y, Oka T, Azuma M. Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res 2001; 22: 470–474
- Weinreb R N, Khaw P T. Primary open-angle glaucoma. Lancet 2004; 363: 1711–1720
- McDonald T O, Hodges J W, Borgmann A R, Leaders F E. The water-loading test in rabbits. A method to detect potential ocular hypotensive drugs. Arch Ophthalmol 1969; 82: 381–384
- van Bijsterveld O P, van Loenen A C, ten Ham M. The effect of hypotensive drugs on the intraocular pressure after waterloading in rabbits. Doc Ophthalmol 1981; 52: 189–198
- Santafé J, Martínez de Ibarreta M J, Segarra J, Melena J. The effect of topical diltiazem on ocular hypertension induced by water loading in rabbits. Gen Pharmacol 1999; 32: 201–205
- Honjo M, Inatani M, Kido N, et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol 2001; 119: 1171–1178
- Nakajima E, Nakajima T, Minagawa Y, et al. Contribution of ROCK in contraction of trabecular meshwork: Proposed mechanism for regulating aqueous outflow in monkey and human eyes. J Pharm Sci 2005; 94: 701–708
- Honjo M, Inatani M, Kido N, et al. A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes. Exp Eye Res 2002; 75: 135–142
- Asano T, Suzuki T, Tsuchiya M, et al. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br J Pharmacol 1989; 98: 1091–1100
- Asano T, Ikegaki I, Satoh S, et al. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987; 241: 1033–1040
- Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)–2–methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002; 93: 225–232
- Masumoto A, Hirooka Y, Shimokawa H, et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38: 1307–1310
- Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174–178
- Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001; 42: 137–144
- Hirata A, Inatani M, Inomata Y, et al. Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia. Graefes Arch Clin Exp Ophthalmol 2008; 246: 51–59
- Mueller B K, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005; 4: 387–398
- Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767–1775
- Rikitake Y, Kim H H, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36: 2251–2257